Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Iclusig (ponatinib; Takeda/Incyte/Otsuka)Drug Analysis Report 2018: A BCR-ABL Tyrosine Kinase Inhibitor (TKI) - ResearchAndMarkets.com

Research and Markets
Posted on: 15 Feb 18

The "Drug analysis: Iclusig" drug pipelines has been added to ResearchAndMarkets.com's offering.

Iclusig (ponatinib; Takeda/Incyte/Otsuka) is a BCR-ABL tyrosine kinase inhibitor (TKI). Preclinical studies have also shown selective inhibition of other tyrosine kinases, including FLT3, RET, KIT, and the members of the fibroblast growth factor receptor, platelet-derived growth factor receptor, and vascular endothelial growth factor receptor families of kinases. Iclusig demonstrated inhibition of wild-type and mutated forms of BCR-ABL, including T315I, the highly drug-resistant missense mutation of BCR-ABL. In mice, treatment with Iclusig reduced the size of tumors expressing native or T315I-mutant BCR-ABL when compared to controls.

After a brief suspension due to an increased risk of arterial thrombosis, Ariad reinstated Iclusig's commercialization for patients with refractory chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia in January 2014. This event was contingent upon US Food and Drug Administration (FDA) requirements that safety measures, additional product labeling, a Risk Evaluation and Mitigation Strategy, and post-marketing investigations be put in place prior to marketing and commercialization.

Key Topics Covered:

List of Figures

Figure 1: Iclusig for CML - SWOT analysis

Figure 2: Drug assessment summary of Iclusig for CML

Figure 3: Drug assessment summary of Iclusig for CML

Figure 4: Iclusig - SWOT analysis in acute lymphoblastic leukemia

Figure 5: Drug assessment summary for Iclusig in acute lymphoblastic leukemia

Figure 6: Drug assessment summary for Iclusig in acute lymphoblastic leukemia

List of Tables

Table 1: Iclusig drug profile

Table 2: Iclusig pivotal trial data in CML

Table 3: Iclusig late-phase trial data in CML

Table 4: Iclusig ongoing late-phase clinical trials in CML

Table 5: Iclusig drug profile

Table 6: Pivotal clinical trial data for Iclusig in acute lymphoblastic leukemia

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/55fcx3/iclusig?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180215006142/en/

Business Wire
www.businesswire.com

Last updated on: 15/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.